LYB001

LYB001
Vaccine description
TargetSARS-CoV-2
Vaccine typeVirus-like particles
Clinical data
Routes of
administration		Intramuscular

LYB001 is a COVID-19 vaccine candidate developed by Yantai Patronus Biotech Co., Ltd.[1][2][3][4]

It was found to be safe and well tolerated.[5]

References

  1. ↑ "Safety, Reactogenicity, and Immunogenicity of a Recombinant SARS-CoV-2 Vaccine LYB001 in healthy adults: a randomized, double blinded, placebo-controlled phase I trial". chictr.org.cn. Chinese Clinical Trial Registry. Retrieved 15 October 2021.
  2. ↑ "A Phase I Trial to Evaluate the Safety and Immunogenicity of SARS-CoV-2 Vaccine LYB001". ClinicalTrials.gov. 18 November 2021. NCT05125926. Retrieved 18 November 2021.
  3. ↑ "Immunogenicity and safety of a SARS-CoV-2 Vaccine LYB001 against COVID-19 in healthy adults: a randomized, double blinded, placebo-controlled phase II trial and a single-armed, open-label expanded safety phase III trial". chictr.org.cn. Chinese Clinical Trial Registry. Retrieved 15 October 2021.
  4. ↑ "Phase II and III Trial of a SARS-CoV-2 Vaccine LYB001". ClinicalTrials.gov. 30 November 2021. NCT05137444. Retrieved 30 November 2021.
  5. ↑ Tang R, Zeng Y, Zhou Y, Liang Q, Kang W, Yang Z, et al. (2 May 2024). "Safety and immunogenicity of the SARS-CoV-2 LYB001 RBD-based VLP vaccine (CHO cell) phase 1 in Chinese adults: a randomized, double-blind, positive-parallel-controlled study". Expert Review of Vaccines. 23 (1): 498–509. doi:10.1080/14760584.2024.2337051. PMID 38695310.
This page is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.